These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29358619)

  • 1. Novel therapeutic strategy for cervical cancer harboring FGFR3-TACC3 fusions.
    Tamura R; Yoshihara K; Saito T; Ishimura R; Martínez-Ledesma JE; Xin H; Ishiguro T; Mori Y; Yamawaki K; Suda K; Sato S; Itamochi H; Motoyama T; Aoki Y; Okuda S; Casingal CR; Nakaoka H; Inoue I; Verhaak RGW; Komatsu M; Enomoto T
    Oncogenesis; 2018 Jan; 7(1):4. PubMed ID: 29358619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
    Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
    Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR3-TACC3: A novel gene fusion in cervical cancer.
    Carneiro BA; Elvin JA; Kamath SD; Ali SM; Paintal AS; Restrepo A; Berry E; Giles FJ; Johnson ML
    Gynecol Oncol Rep; 2015 Aug; 13():53-6. PubMed ID: 26425723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation.
    Nelson KN; Meyer AN; Siari A; Campos AR; Motamedchaboki K; Donoghue DJ
    Mol Cancer Res; 2016 May; 14(5):458-69. PubMed ID: 26869289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity.
    Agaimy A; Antonescu CR; Bell D; Breimer GE; Dermawan JK; Kester LA; Laco J; Rijken JA; Whaley RD; Stoehr R; Cramer T; Bishop JA
    Virchows Arch; 2024 Oct; ():. PubMed ID: 39387893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling.
    Nelson KN; Meyer AN; Wang CG; Donoghue DJ
    Oncotarget; 2018 Sep; 9(76):34306-34319. PubMed ID: 30344944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
    Weickhardt AJ; Lau DK; Hodgson-Garms M; Lavis A; Jenkins LJ; Vukelic N; Ioannidis P; Luk IY; Mariadason JM
    BMC Cancer; 2022 May; 22(1):478. PubMed ID: 35501832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.
    Picca A; Sansone G; Santonocito OS; Mazzanti CM; Sanson M; Di Stefano AL
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability.
    Wang CG; Peiris MN; Meyer AN; Nelson KN; Donoghue DJ
    Oncotarget; 2023 Feb; 14():133-145. PubMed ID: 36780330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RT-PCR assay to detect
    Priesterbach-Ackley LP; van Kuik J; Tops BBJ; Lasorella A; Iavarone A; van Hecke W; Robe PA; Wesseling P; de Leng WWJ
    Neurooncol Pract; 2024 Apr; 11(2):142-149. PubMed ID: 38496910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a degrader against oncogenic fusion protein FGFR3-TACC3.
    Shibata N; Cho N; Koyama H; Naito M
    Bioorg Med Chem Lett; 2022 Mar; 60():128584. PubMed ID: 35085722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 signaling and function in triple negative breast cancer.
    Chew NJ; Nguyen EV; Su SP; Novy K; Chan HC; Nguyen LK; Luu J; Simpson KJ; Lee RS; Daly RJ
    Cell Commun Signal; 2020 Jan; 18(1):13. PubMed ID: 31987043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked.
    Nassar AH; Lundgren K; Pomerantz M; Van Allen E; Harshman L; Choudhury AD; Preston MA; Steele GS; Mouw KW; Wei XX; McGregor BA; Choueiri TK; Bellmunt J; Kwiatkowski DJ; Sonpavde GP
    JCO Precis Oncol; 2018; 2():. PubMed ID: 33604498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3-TACC3 fusion in solid tumors: mini review.
    Costa R; Carneiro BA; Taxter T; Tavora FA; Kalyan A; Pai SA; Chae YK; Giles FJ
    Oncotarget; 2016 Aug; 7(34):55924-55938. PubMed ID: 27409839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs.
    Georgescu MM; Islam MZ; Li Y; Traylor J; Nanda A
    Acta Neuropathol Commun; 2021 Apr; 9(1):69. PubMed ID: 33853673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
    McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
    Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.